Dyadic International (DYAI) Competitors $0.93 -0.01 (-0.96%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.95 +0.02 (+1.83%) As of 07/3/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYAI vs. GLSI, FATE, PLX, NKTX, CRBU, ACTU, CRDL, ATOS, KRRO, and VXRTShould you be buying Dyadic International stock or one of its competitors? The main competitors of Dyadic International include Greenwich LifeSciences (GLSI), Fate Therapeutics (FATE), Protalix BioTherapeutics (PLX), Nkarta (NKTX), Caribou Biosciences (CRBU), Actuate Therapeutics (ACTU), Cardiol Therapeutics (CRDL), Atossa Genetics (ATOS), Korro Bio (KRRO), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Dyadic International vs. Its Competitors Greenwich LifeSciences Fate Therapeutics Protalix BioTherapeutics Nkarta Caribou Biosciences Actuate Therapeutics Cardiol Therapeutics Atossa Genetics Korro Bio Vaxart Greenwich LifeSciences (NASDAQ:GLSI) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment. Which has preferable valuation & earnings, GLSI or DYAI? Dyadic International has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$15.79M-$1.26-7.96Dyadic International$3.49M8.03-$5.81M-$0.20-4.66 Do analysts prefer GLSI or DYAI? Greenwich LifeSciences currently has a consensus price target of $39.00, suggesting a potential upside of 288.64%. Dyadic International has a consensus price target of $6.00, suggesting a potential upside of 544.47%. Given Dyadic International's higher probable upside, analysts clearly believe Dyadic International is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyadic International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GLSI or DYAI more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Dyadic International's net margin of -163.94%. Dyadic International's return on equity of -233.69% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -450.87% -333.18% Dyadic International -163.94%-233.69%-59.37% Which has more volatility and risk, GLSI or DYAI? Greenwich LifeSciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Do institutionals and insiders hold more shares of GLSI or DYAI? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by insiders. Comparatively, 29.5% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer GLSI or DYAI? In the previous week, Dyadic International had 1 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 1 mentions for Dyadic International and 0 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 0.00 equaled Dyadic International'saverage media sentiment score. Company Overall Sentiment Greenwich LifeSciences Neutral Dyadic International Neutral SummaryDyadic International beats Greenwich LifeSciences on 9 of the 12 factors compared between the two stocks. Get Dyadic International News Delivered to You Automatically Sign up to receive the latest news and ratings for DYAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYAI vs. The Competition Export to ExcelMetricDyadic InternationalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.01M$2.88B$5.49B$9.02BDividend YieldN/A2.43%5.38%4.09%P/E Ratio-4.6521.5627.4720.28Price / Sales8.03244.81408.30121.41Price / CashN/A41.9536.6357.47Price / Book11.647.518.095.67Net Income-$5.81M-$55.05M$3.17B$248.96M7 Day Performance-6.80%4.61%2.82%3.30%1 Month Performance-4.02%4.89%3.69%5.20%1 Year Performance-37.09%5.84%35.42%21.37% Dyadic International Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYAIDyadic International2.0309 of 5 stars$0.93-1.0%$6.00+544.5%-36.7%$28.01M$3.49M-4.657Gap DownHigh Trading VolumeGLSIGreenwich LifeSciences1.5333 of 5 stars$9.07+0.9%$39.00+330.0%-39.9%$120.18MN/A-7.203FATEFate Therapeutics4.1572 of 5 stars$1.12+7.7%$3.83+242.3%-63.8%$119.19M$13.63M-0.75550News CoverageAnalyst RevisionGap UpPLXProtalix BioTherapeutics2.9618 of 5 stars$1.48-3.9%$15.00+913.5%+45.8%$117.82M$59.76M-11.38200Gap UpNKTXNkarta2.2867 of 5 stars$1.66flat$14.33+763.5%-67.2%$117.79MN/A-1.10140CRBUCaribou Biosciences2.3387 of 5 stars$1.26flat$8.50+574.6%-15.0%$117.19M$9.99M-0.78100News CoverageACTUActuate Therapeutics2.9949 of 5 stars$6.11+2.5%$20.50+235.5%N/A$116.93MN/A0.0010Positive NewsHigh Trading VolumeCRDLCardiol Therapeutics2.0924 of 5 stars$1.36-3.5%$8.00+488.2%-21.0%$116.54MN/A-4.0020ATOSAtossa Genetics1.4907 of 5 stars$0.83-5.6%$6.17+643.0%-29.3%$113.61MN/A-3.958News CoverageKRROKorro Bio2.4037 of 5 stars$12.49+3.8%$102.43+720.1%-66.3%$112.97M$2.27M-1.3270Positive NewsVXRTVaxart2.3044 of 5 stars$0.45-8.6%$3.00+563.7%-33.1%$112.90M$28.70M-1.67120 Related Companies and Tools Related Companies Greenwich LifeSciences Alternatives Fate Therapeutics Alternatives Protalix BioTherapeutics Alternatives Nkarta Alternatives Caribou Biosciences Alternatives Actuate Therapeutics Alternatives Cardiol Therapeutics Alternatives Atossa Genetics Alternatives Korro Bio Alternatives Vaxart Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYAI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyadic International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyadic International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
